First Tracks Biotherapeutics, Inc. (TRAX) News
Follow First Tracks Biotherapeutics, Inc. (TRAX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
First Tracks Biotherapeutics Reports Third-Quarter Net Loss of $31.4M
The company’s diluted loss per share narrowed to $0.88 from $1.50 a year earlier. It also reported progress across its ANB033 and rosnilimab programs.
EQUITY | Nov 03, 2026, 09:40 PM UTC
M
First Tracks Biotherapeutics Reports Third-Quarter 2026 Results and Business Update
The company said ANB033 achieved a statistically significant and clinically meaningful protective effect; the available report is truncated before providing further details.
EQUITY | Nov 03, 2026, 09:25 PM UTC
M
First Tracks Biotherapeutics Secures $200 Million Private Placement
The company agreed to sell 6,106,870 common shares at $32.75 each to certain third-party investors, for expected gross proceeds of approximately $200 million. The placement is expected to close October 19, 2026.
EQUITY | Oct 15, 2026, 08:35 PM UTC
M
First Tracks Biotherapeutics Reports Positive Phase 1b ANB033 Results
The company said ANB033 showed statistically significant protection against gluten-induced intestinal damage and symptoms.
EQUITY | Oct 13, 2026, 12:43 PM UTC
M
TRAX Reports Positive Celiac Study Results; MIRM Meets Phase 3 Endpoint
Premarket mover roundup also includes TRMD’s full-year guidance upgrade, talk of advanced sale talks involving CCC, and BMY’s positive interim Phase 3 ACTION-1 results. The source also cites analyst upgrades for CRM, BII
EQUITY | Oct 12, 2026, 01:08 PM UTC
L
First Tracks Biotherapeutics reports positive ANB033 study results
The company announced positive top-line results for ANB033 in a gluten-challenge study in celiac disease.
EQUITY | Oct 12, 2026, 11:00 AM UTC
M
First Tracks Shares Rise 15% Ahead of Celiac Trial Data Review
First Tracks Biotherapeutics said it would review top-line data from a celiac disease treatment trial on Monday. Shares rose 15% to $36.71 in premarket trading; they were up nearly 68% year to date through Friday's close
EQUITY | Oct 12, 2026, 10:13 AM UTC
H
Stock Market Today: S&P 500, Dow Jones Futures Gain Even as Iran Flags 'Inadequate' US Response to Peace Terms — SMP, QMCO, SVRN in Focus
U.S. stock futures were mixed on Monday, as the Dow Jones and S&P 500 indices rose, while the Nasdaq 100 index fell, following Friday’s higher close. Geopolitical tensions flared over the weekend as Iran stepped up attac
LIVE | Oct 12, 2026, 09:35 AM UTC
L
First Tracks Biotherap Initiated at Buy by Canaccord Genuity
Ratings actions from Benzinga
NEWS | Sep 30, 2026, 11:47 AM UTC
L
TRAX: Advancing dual-mechanism CD122 therapy in celiac and EoE, with key data and expansion ahead
The company, newly formed and well-funded, is advancing a pipeline led by ANB033, a dual-mechanism CD122 antagonist targeting autoimmune diseases, with phase I-B trials in celiac disease and EoE. Data readouts are expect
EQUITY | Sep 09, 2026, 03:26 PM UTC
L
TRAX advances CD122 antibody for celiac and EoE; phase I-B soon
TRAX, newly formed from a spinout, is developing a dual-mechanism CD122 antibody for celiac disease and EoE. Phase I-B data are expected soon, with plans to expand into additional indications.
EQUITY | Sep 09, 2026, 02:38 PM UTC
L
TRAX director sells common shares worth $1,758,145
Director Ware J. Anthony reported selling common stock on 2026-09-02 at a weighted average price of $44.7764 per share, for $1,758,145 total.
EQUITY | Sep 04, 2026, 08:31 PM UTC
L
First Tracks Biotherap price target held at $57.00
HC Wainwright & Co. maintained a $57.00-per-share price target for First Tracks Biotherap, according to TradingView News via Benzinga.
EQUITY | Sep 03, 2026, 11:54 AM UTC
L
First Tracks Biotherapeutics to participate in September investor conferences
First Tracks Biotherapeutics announced it will participate in September investor conferences.
EQUITY | Aug 26, 2026, 08:17 PM UTC
L
TRAX - First Tracks Biotherapeutics Announces Participation in September Investor Conferences
TRAX - First Tracks Biotherapeutics Announces Participation in September Investor Conferences
EQUITY | Aug 26, 2026, 08:15 PM UTC
L
TRAX Announces Q2 2026 Financial Results
TRAX announces second quarter 2026 financial results and provides business update
EARNINGS | Aug 12, 2026, 08:16 PM UTC
L
First Tracks Biotherapeutics price target raised by $8 at Barclays, here's why
First Tracks Biotherapeutics price target raised by $8 at Barclays, here's why
EQUITY | Jul 21, 2026, 10:20 AM UTC